163 related articles for article (PubMed ID: 26652645)
1. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.
Li X; Zhu S; Hong C; Cai H
Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
Wang H; Xu T; Zheng L; Li G
Int J Gynecol Cancer; 2018 Jun; 28(5):903-914. PubMed ID: 29561301
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis.
Yi S; Zeng L; Kuang Y; Cao Z; Zheng C; Zhang Y; Liao M; Yang L
Onco Targets Ther; 2017; 10():973-984. PubMed ID: 28255243
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis.
Li J; Li S; Chen R; Yu H; Lu X
J Ovarian Res; 2015 Aug; 8():54. PubMed ID: 26242216
[TBL] [Abstract][Full Text] [Related]
8. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
Li J; Zhou L; Chen X; Ba Y
Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
[TBL] [Abstract][Full Text] [Related]
9. Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment.
Ding SS; Li L; Yu CX
J BUON; 2014; 19(4):965-72. PubMed ID: 25536603
[TBL] [Abstract][Full Text] [Related]
10. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.
Marchetti C; De Felice F; Palaia I; Musella A; Di Donato V; Gasparri ML; Musio D; Muzii L; Tombolini V; Panici PB
Oncotarget; 2016 Mar; 7(11):13221-7. PubMed ID: 26657509
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
Ye Q; Chen HL
Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer.
Wang TS; Lei W; Cui W; Wen P; Guo HF; Ding SG; Yang YP; Xu YQ; Lv SW; Zhu YL
Indian J Cancer; 2014 Mar; 51 Suppl 3():e95-8. PubMed ID: 25818743
[TBL] [Abstract][Full Text] [Related]
14. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Liu S; Kasherman L; Fazelzad R; Wang L; Bouchard-Fortier G; Lheureux S; Krzyzanowska MK
Gynecol Oncol; 2021 May; 161(2):601-612. PubMed ID: 33546867
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
Li X; Wang H; Lin W; Xu Q
Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
[TBL] [Abstract][Full Text] [Related]
16. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
Zhou M; Yu P; Qu X; Liu Y; Zhang J
PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.
Lin Z; Yang Y; Huang Y; Liang J; Lu F; Lao X
Mol Clin Oncol; 2015 Jul; 3(4):959-967. PubMed ID: 26171215
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.
Yu S; Xu Q; Yuan Y; Li X; Cai H
Curr Med Res Opin; 2016 Dec; 32(12):1927-1934. PubMed ID: 27479336
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S
Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101
[TBL] [Abstract][Full Text] [Related]
20. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
